Characterization of 17-dihydroexemestane glucuronidation: Potential role of the UGT2B17 deletion in exemestane pharmacogenetics

Pharmacogenetics and Genomics

Volumn 20, Issue 10, 2010, Pages 575-585

  Sun, Dongxiao ^a   Chen, Gang ^a   Dellinger, Ryan W ^a   Sharma, Arun K ^a,b   Lazarus, Philip ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

aromatase inhibitor; breast cancer; exemestane 17 dihydroexemestane; glucuronidation; metabolism; pharmacogenetics; UDP glucuronosyltransferase

Indexed keywords

17 DIHYDROEXEMESTANE; ANDROSTENEDIONE; AROMATASE INHIBITOR; EXEMESTANE; EXEMESTANE 17 O GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2B17; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GENE DELETION; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HOMOGENATE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77957243014     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833b04af     Document Type: Article

References (47)

1. US National Institutes of Health. 2009 [cited; Available from: http:// www.cancer.gov/cancertopics/types/breast]
2. Howell A, Howell SJ, Evans DG. New approaches to the endocrine prevention and treatment of breast cancer. Cancer Chemother Pharmacol 2003; 52 (Suppl 1):S39-S44. (Pubitemid 37047023)
3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388. (Pubitemid 28439961)
4. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-1618.
5. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361:296-300. (Pubitemid 36126189)
6. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T,Wilking N; Stockholm Breast Cancer Study Group. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87:645-651.
7. Van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343:448-452. (Pubitemid 24059587)
8. Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, et al. Secondand third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 2006; 94:1789-1796. (Pubitemid 43882568)
9. Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 2008; 34:157-174.
10. Deeks ED, Scott LJ. Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs 2009; 69:889-918.
11. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005; 365:60-62. (Pubitemid 40082147)
12. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486-492. (Pubitemid 350002953)
13. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8:119-127. (Pubitemid 46158372)
14. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole vs. placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629-3635. (Pubitemid 46630537)
15. Karaer O, Oruc S, Koyuncu FM. Aromatase inhibitors: possible future applications. Acta Obstet Gynecol Scand 2004; 83:699-706. (Pubitemid 39062142)
16. Grana G. Adjuvant aromatase inhibitor therapy for early breast cancer: a review of the most recent data. J Surg Oncol 2006; 93:585-592. (Pubitemid 43806995)
17. Lonning PE. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res Treat 1998; 49 (Suppl 1):S45-S52. discussion S73-S77. (Pubitemid 28427260)
18. Evans TR, Di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992; 52:5933-5939.
19. Mareck U, Geyer H, Guddat S, Haenelt N, Koch A, Kohler M, et al. Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2006; 20:1954-1962. (Pubitemid 43893351)
20. Di Salle E, Ornati G, Paridaens R, Coombes RC, Lobelle JP, Zurlo MG. Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In: Motta M, Serio M, editors. Sex hormones and antihormones in endocrine dependent pathology: basic and clinical aspects. Amsterdam: Elsevier; 1994. pp. 279-286.
21. Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, et al. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat 2008; 111:377-388.
22. Aromasin Exemestane Tablets. 2007 [cited; Available from: http:// www.pfizer.com/files/products/uspi-aromasin.pdf]
23. Buzzetti F, Di Salle E, Longo A, Briatico G. Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1, 4-diene-3,17-dione). Steroids 1993; 58:527-532. (Pubitemid 23336094)
24. Ariazi EA, Leitao A, Oprea TI, Chen B, Louis T, Bertucci AM, et al. Exemestanes 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther 2007; 6:2817-2827. (Pubitemid 350206762)
25. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDPglucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 2004; 64:1190-1196. (Pubitemid 38176928)
26. Coughtrie MW, Burchell B, Bend JR. A general assay for UDPglucuronosyltransferase activity using polar amino-cyano stationary phase HPLC and UDP[U-14C]glucuronic acid. Anal Biochem 1986; 159:198-205. (Pubitemid 17228246)
27. Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer AM, Chase GA, et al. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sexspecific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:823-828. (Pubitemid 46650589)
28. Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, Lazarus P. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 2009; 69:2981-2989.
29. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 2007; 35:2006-2014. (Pubitemid 350010805)
30. Wiener D, Doerge DR, Fang JL, Upadhyaya P, Lazarus P. Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol (NNAL) in human liver: importance of UDPglucuronosyltransferase 1A4. Drug Metab Dispos 2004; 32:72-79. (Pubitemid 38112538)
31. Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, et al. Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDPglucuronosyltransferase enzymes. Cancer Res 2002; 62:1978-1986. (Pubitemid 34408441)
32. Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P. Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. Carcinogenesis 2007; 28:2412-2418. (Pubitemid 350111602)
33. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 2009; 37:1759-1768.
34. Itaaho K, Court MH, Uutela P, Kostiainen R, Radominska-Pandya A, Finel M. Dopamine is a low-affinity and high-specificity substrate for the human UDPglucuronosyltransferase 1A10. Drug Metab Dispos 2009; 37:768-775.
35. Lazarus P, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev 42:176-188.
36. Wilson W III, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84:707-714. (Pubitemid 39310948)
37. Dellinger RW, Fang JL, Chen G,Weinberg R, Lazarus P. Importance of udpglucuronosyltransferase 1a10 (ugt1a10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the ugt1a10139lys isoform. Drug Metab Dispos 2006; 34:943-949. (Pubitemid 43763749)
38. Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Amin S, Lazarus P, et al. Functional significance of polymorphic variants of UDPglucuronosyltransferase (UGTs) active against tamoxifen metabolites. Cancer Res 2009; 69:1892-1900.
39. Gallagher CJ, Ahn K, Knipe AL, Dyer AM, Richie JP Jr, Lazarus P, et al. Association between haplotypes of manganese superoxide dismutase (SOD2), smoking, and lung cancer risk. Free Radic Biol Med 2009; 46:20-24.
40. Jannuzzo MG, Poggesi I, Spinelli R, Rocchetti M, Cicioni P, Buchan P. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 2004; 53:475-481. (Pubitemid 38680244)
41. Strassburg CP, Oldhafer K, Manns MP, Tukey RH. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 1997; 52:212-220. (Pubitemid 27349612)
42. Strassburg CP, Manns MP, Tukey RH. Expression of the UDPglucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 1998; 273:8719-8726.
43. Lehmann L, Wagner J. Gene expression of 17beta-estradiol-metabolizing isozymes: comparison of normal human mammary gland to normal human liver and to cultured human breast adenocarcinoma cells. Adv Exp Med Biol 2008; 617:617-624.
44. Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A. Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 2008; 73:611-620.
45. Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, Wiener D. Genotypephenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 2005; 15:769-778. (Pubitemid 41531726)
46. Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp> Tyr) polymorphism. Cancer Res 2007; 67:9024-9029. (Pubitemid 47535885)
47. Corona G, Elia C, Casetta B, Diana C, Rosalen S, Bari M, et al. A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma. J Mass Spectrom 2009; 44:920-928.